AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Shares of AbbVie Inc. rose 3.38% to $192.34 Monday, on what proved to be an all-around great trading session for the stock ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential. The healthcare ...

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience ...

Shares of AbbVie Inc. ABBV advanced 1.88% to $180.37 Thursday, on what proved to be an all-around favorable trading session ...

AbbVie Inc (ABBV) surpasses expectations with robust sales growth in Skyrizi and Rinvoq, while navigating challenges in ...

Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Roopal Thakkar; Executive Vice President, Research & Development, Chief Scientific Officer; AbbVie Inc Scott Reents ...

AbbVie Inc.’s (NYSE:ABBV) year is off to a very strong start. The company beat Q1 2025 revenue and EPS estimates and raised the full-year EPS guidance range by $0.10 and the full-year revenue ...

AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments, but warned its forecast doesn’t take into account any potential changes in ...

U.S. stock futures continued to rise on Friday, following a three-day back-to-back winning streak in the regular session, ...

AbbVie Inc.'s Q1 earnings show an 8.4% revenue increase, driven by strong performance in immunology, neuroscience, and oncology divisions, with Skyrizi and Rinvoq leading growth. Despite Humira's ...

AbbVie Inc. (ABBV) on Friday reported first-quarter profit of $1.29 billion. The North Chicago, Illinois-based company said it had net income ...